Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
Siyao HeXin QianYanyan ChenXiaoxia ShenBo ZhangXiaoping ChenXiangjin XuGuangwei LiPublished in: Journal of diabetes research (2021)
In this analysis of electronic health record data from a large database in China, metformin as first-line monotherapy greatly reduced the risk of all-cause death, cardiovascular death, and heart failure in diabetes patients as compared with nonmetformin medications.
Keyphrases
- electronic health record
- heart failure
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- clinical decision support
- adverse drug
- ejection fraction
- combination therapy
- type diabetes
- left ventricular
- cardiovascular disease
- peritoneal dialysis
- prognostic factors
- atrial fibrillation
- acute heart failure
- randomized controlled trial
- emergency department
- metabolic syndrome
- clinical trial
- machine learning
- study protocol
- double blind